Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

BACKGROUND: Inhibitors targeting immune checkpoint were proved effective in cancer immunotherapy, such as PD-1/PD-L1 blockade. The novel immune checkpoint TIGIT/PVR plays critical roles in suppressing the anti-tumor effects of CD8(+) T and NK cells, and dual blockade of TIGIT/PVR and PD-1/PD-L1 by a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Commun Signal
Egile Nagusiak: Zhou, Xiuman, Du, Jiangfeng, Wang, Hongfei, Chen, Chunxia, Jiao, Ling, Cheng, Xiangrui, Zhou, Xiaowen, Chen, Shaomeng, Gou, Shanshan, Zhao, Wenshan, Zhai, Wenjie, Chen, Junhui, Gao, Yanfeng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7487564/
https://ncbi.nlm.nih.gov/pubmed/32894141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12964-020-00638-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak